Association of PDCD1 gene markers with susceptibility to thyroid cancer

被引:19
作者
Haghshenas, M. R. [1 ]
Dabbaghmanesh, M. H. [2 ]
Miri, A. [1 ]
Ghaderi, A. [1 ]
Erfani, N. [1 ]
机构
[1] Shiraz Univ Med Sci, Shiraz Inst Canc Res, Sch Med, Canc Immunol Grp, Shiraz, Iran
[2] Shiraz Univ Med Sci, Nemazee Hosp, Endocrinol & Metab Res Ctr, Shiraz, Iran
关键词
Thyroid cancer; PD-1; Polymorphism; SYSTEMIC-LUPUS-ERYTHEMATOSUS; POLYMORPHISM PD-1.5 C/T; CD8; T-CELLS; RHEUMATOID-ARTHRITIS; PERIPHERAL-BLOOD; BREAST-CANCER; TUMOR; RISK; LYMPHOCYTES; POPULATION;
D O I
10.1007/s40618-016-0579-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose PD-1 receptor is a co-signaling molecule with an important role in regulation of T-lymphocyte activity. Correlation between PD-1 gene (PDCD1) polymorphisms and some immune-related diseases has been reported before. In current study, we aimed to investigate the association of PD-1 polymorphisms at positions +7146 G/A (PD-1.3) and +7785 C/T (PD-1.5), as well as the emerged haplotypes with susceptibility to thyroid carcinoma. Methods One hundred five patients with confirmed thyroid cancer and 160 healthy individuals as control group were enrolled. Genotypes were identified using PCR-RFLP and nested PCR-RFLP methods. Results were analyzed by Arlequin and SPSS software packages. Results Analysis revealed a significant increase in the frequency of PD-1.5 mutant T allele and heterozygous CT genotype in patients with thyroid cancer in comparison with controls [79 (37.7%) vs. 71 (22.2%), and 51 (48.6%) vs. 51 (31.9%), p = 0.0001 and p = 0.009, receptively]. CC genotype at this position observed to be significantly higher among controls than the patients [99 (61.9%) vs. 40 (38.1%), p = 0.0002]. There were no significant differences in the frequencies of genotypes and alleles at locus PD-1.3 between patients and control group. Despite this, GT haplotype emerged from both positions (PD-1.3 G and PD-1.5 T) has also been observed with significant increased frequency between patients and controls [70 (36.8%) vs. 71 (22.2%), p = 0.0005]. Conclusion As the first study to investigate two mentioned polymorphisms in thyroid cancer, current study confirmed the association of PD-1.5 C/T polymorphism and a haplotype resulted from both loci, PD-1.3 and PD-1.5, with susceptibility of Iranians to thyroid cancer.
引用
收藏
页码:481 / 486
页数:6
相关论文
共 38 条
  • [1] Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
    Ahmadzadeh, Mojgan
    Johnson, Laura A.
    Heemskerk, Bianca
    Wunderlich, John R.
    Dudley, Mark E.
    White, Donald E.
    Rosenberg, Steven A.
    [J]. BLOOD, 2009, 114 (08) : 1537 - 1544
  • [2] [Anonymous], 2014, J. Appl. Math
  • [3] Lack of an association of programmed cell death-1 PD1.3 polymorphism with risk of hepatocellular carcinoma susceptibility in Turkish population: A case-control study
    Bayram, Suleyman
    Akkiz, Hikmet
    Ulger, Yakup
    Bekar, Aynur
    Akgollu, Ersin
    Yildirim, Selcuk
    [J]. GENE, 2012, 511 (02) : 308 - 313
  • [4] Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy
    Blank, C
    Gajewski, TF
    Mackensen, A
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (04) : 307 - 314
  • [5] Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland
    Ciampi, R.
    Romei, C.
    Pieruzzi, L.
    Tacito, A.
    Molinaro, E.
    Agate, L.
    Bottici, V.
    Casella, F.
    Ugolini, C.
    Materazzi, G.
    Basolo, F.
    Elisei, R.
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2017, 40 (01) : 55 - 62
  • [6] PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy
    Dolan, Dawn E.
    Gupta, Shilpa
    [J]. CANCER CONTROL, 2014, 21 (03) : 231 - 237
  • [7] PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer
    Dulos, John
    Carven, Gregory J.
    van Boxtel, Susan J.
    Evers, Sabine
    Driessen-Engels, Lilian J. A.
    Hobo, Willemijn
    Gorecka, Monika A.
    de Haan, Anton F. J.
    Mulders, Peter
    Punt, Cornelis J. A.
    Jacobs, Joannes F. M.
    Schalken, Jack A.
    Oosterwijk, Egbert
    van Eenennaam, Hans
    Boots, Annemieke M.
    [J]. JOURNAL OF IMMUNOTHERAPY, 2012, 35 (02) : 169 - 178
  • [8] Arlequin (version 3.0): An integrated software package for population genetics data analysis
    Excoffier, Laurent
    Laval, Guillaume
    Schneider, Stefan
    [J]. EVOLUTIONARY BIOINFORMATICS, 2005, 1 : 47 - 50
  • [9] PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
    Francisco, Loise M.
    Salinas, Victor H.
    Brown, Keturah E.
    Vanguri, Vijay K.
    Freeman, Gordon J.
    Kuchroo, Vijay K.
    Sharpe, Arlene H.
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2009, 206 (13) : 3015 - 3029
  • [10] Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
    Freeman, GJ
    Long, AJ
    Iwai, Y
    Bourque, K
    Chernova, T
    Nishimura, H
    Fitz, LJ
    Malenkovich, N
    Okazaki, T
    Byrne, MC
    Horton, HF
    Fouser, L
    Carter, L
    Ling, V
    Bowman, MR
    Carreno, BM
    Collins, M
    Wood, CR
    Honjo, T
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (07) : 1027 - 1034